People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Clarametyx Biosciences, Inc. | — | Biotechnology | Series B | $27.5M | $242.1M | 2024 |
Michael Triplett II at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Triplett II on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Richards | 1 | 4 |
| Michael G. Layman | 1 | 3 |
| Peter G. Kleinhenz | 1 | 2 |
| Larry G. Edwards | 1 | 1 |
| William G. Baumel | 1 | 1 |
| Wayne G. Embree | 1 | 1 |
| Chuck G. Bramlage | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.